Refine by
Cytokines Articles & Analysis
106 news found
Chronic Obstructive Pulmonary Disease (COPD) is a global health burden characterized by persistent airflow limitation and progressive lung damage. Despite extensive research, translating findings from bench to bedside remains a challenge. Precision Cut Lung Slices (PCLS) have emerged as a versatile tool in COPD research, offering unique advantages for understanding disease mechanisms and ...
Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition characterized by increased pulmonary arterial pressure, vascular remodeling, and persistent inflammation. Despite advances in treatment, current therapies—such as sildenafil, iloprost, and riociguat—primarily focus on reducing symptoms by dilating blood vessels. Unfortunately, these therapies do ...
Additionally, Creative Diagnostics provides valuable data on viral disease progression, histology, immunohistochemistry, immunoassays, flow cytometry, cellular infiltration, cytokines, viral titers, LD50 studies, and vaccine/treatment efficacy. ...
Creative BioMart stays at the forefront of industry demands by continually launching popular product categories. These include cytokines, PROTAC targets, GPCRs, labeled proteins, full-length proteins, virus-related proteins, CAR-T cell targets, biomarkers, CD antigens, and more. ...
Key presentations on Bayer research to be presented at AACR 2023 are listed below: Oral presentation: BAY 2965501: A highly selective DGKzeta inhibitor for cancer immuno-therapy with first-in-class potential Abstract ND04, Session DDT001 – New Drugs on the Horizon: Part 1 Sunday, April 16, 2:05 PM – 2:20 PM (EDT), Tangerine Ballroom 2 (WF2) - Convention Center Poster ...
ByBayer AG
In addition, Creative Diagnostics possesses a variety of ELISA kits for the detection of hundreds of different proteins and molecules, including cytokines, growth factors, markers of infectious diseases, diabetes and tumors, small molecular drugs, and more. ...
Cytokine, a subdivision of Creative Proteomics, specializes in providing cytokine research and analytical services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Recently, the product manager of the company was pleased to announce the launch of its Cancer Cytokines ...
Cytokine, a subdivision of Creative Proteomics, specializes in providing cytokine research and analytical services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Recently, the product manager of the company is pleased to announce the launch of the growth factors (GF) detection service ...
In the safety analysis of these 7 patients, adverse events were consistent with the known toxicities of CD19 CAR-T treatment. No grade 3 or higher cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) was observed in any of the patients. ...
Functional protein molecules are usually endogenous ligands (or corresponding receptors), such as cytokines, growth factors, hormones, enzymes, or other active substances, while fusion partners mainly include immunoglobulins, albumins, or transferrins. ...
He has led the Company in creating a diverse clinical-stage portfolio of engineered antibodies and cytokines for the treatment of life-threatening and debilitating diseases, and has established alliances with leading biopharmaceutical companies that have resulted in three marketed drugs. ...
Glycoproteins, such as glycosyltransferases, glycosidases, erythropoietin, and cytokines, make up the majority of biotherapeutic products. Although the drugs themselves are complicated, it is urgent to develop techniques to characterize glycosylation in order to better evaluate their effects. ...
No DLTs or greater than grade 3 events of acute or chronic graft versus host disease (GvHD), cytokine release syndrome (CRS), or immune effector cell neurotoxicity syndrome (ICANS) have been observed. ...
Safety profile continues to be manageable with no dose-limiting toxicities, no treatment-related Grade 3 or greater adverse events, including graft versus host disease (GvHD), and no cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). ...
(“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has been dosed in a Phase 1 study of an investigational candidate resulting from the collaboration between Sutro and Merck, known as MSD outside the United States and Canada, for the ...
The Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently launched the Mouse Cytokine Assay with high ...
Umoja’s iPSCs are engineered with a synthetic rapamycin-activated cytokine receptor (RACR™) to drive differentiation to, and expansion of innate cytotoxic lymphoid cells, including but not limited to natural killer (NK) cells in the absence of exogenous cytokines and feeder cells. ...
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitors In vivo studies of an AML murine model demonstrated anti-tumor efficacy; ...
Uses of Proceeds and Planned Milestones Proceeds from the transaction are expected to provide Senti Bio with capital to further develop its gene circuit technologies and therapeutic pipeline, including: Conducting Investigational New Drug- (IND) enabling studies for SENTI-202 and SENTI-301 Building out clinical-scale current good manufacturing practice (cGMP) capabilities and enabling cGMP ...
There were no cases of graft rejection and no episodes of graft versus host disease or cytokine release syndrome. One patient developed de novo donor-specific antibodies; these antibodies were not found to be directed against posoleucel antigens in the matching cell line. ...
ByKalaris